1. Home
  2. WINT

as 06-27-2025 3:33pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

Founded: 1992 Country:
United States
United States
Employees: N/A City: WARRINGTON
Market Cap: 2.2M IPO Year: 1995
Target Price: $350.00 AVG Volume (30 days): 7.1M
Analyst Decision: Hold Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -64.36 EPS Growth: N/A
52 Week Low/High: $0.36 - $737.43 Next Earning Date: 08-18-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

WINT Daily Stock ML Predictions

Share on Social Networks: